John Bell has resigned his position as chairman of Oxford-based clinical AI technology company Sensyne Health due to a potential conflict of interest. Bell currently advises the government on its strategy for life sciences.

Non-executive director Charles Swingland is taking over as interim chairman until a replacement is found, when he will return to his old role.

Sensyne chief executive Paul Drayson said: “On behalf of the board, I thank John for his significant contribution to this company and his leadership of the board through the successful IPO. Sensyne is committed to transparency and good corporate governance so we understand his obligation to step away as we pursue our commitment to improve patient health, medical practices and NHS healthcare costs and efficiencies through the analysis of both larger volumes of anonymised UK patient data and additional healthcare data sets.”